Companies › Vertanical
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VER-01 Cannabis sativa extract containing Δ9-tetrahydrocannabinol (THC) - cannabinoid receptor ag | CNR1, CNR2 | Phase 3 | Lumbosacral Radiculopathy | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06956014 | VER-01 | Phase 3 | Lumbosacral Radiculopathy | Other | Sep 2028 |
IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
Zynerba Pharmaceuticals Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.